Aspirin has been effective for acute migraines both as a solitary modality and in combination with other drugs, and thus has clinical value in treatment and prophylaxis of the migraines overall.
In a randomized, placebo-controlled crossover study, researchers determined the effect of a 2-hour vasoactive intestinal polypeptide infusion on risk for migraine attacks.
The approval is supported by data from the phase 3 STOP 301 study, which evaluated the safety and tolerability of Trudhesa in 354 adults with migraine.
